Please login to the form below
ipilimumab
This page shows the latest ipilimumab news and features for those working in and with pharma, biotech and healthcare.
AZ still sees route to approval for Imfinzi in MYSTIC trial
BMS is testing the FDA’s view on this with an application for Opdivo plus its CTLA4 inhibitor Yervoy (ipilimumab) in first-line patients with TMB above 10 mutations per megabase,
Latest news
-
NICE U-turn sees Opdivo backed as adjuvant therapy for skin cancer
In the meantime, BMS will collect further data from CheckMate238, which has already shown that Opdivo improves recurrence-free survival compared to Yervoy (ipilimumab), as it aims for a routine licence.
-
Roche pulls EU Tecentriq/Avastin filing in kidney cancer
Bristol-Myers Squibb’s combination of PD-1 inhibitor Opdivo (nivolumab) and CTLA4 inhibitor Yervoy (ipilimumab) had been turned down by the CHMP earlier this year on the grounds that adding
-
BMS CEO tackles investor ‘frustrations’ on immuno-oncology
BMS was the pathfinder for the checkpoint inhibitor market with its CTLA4 inhibitor Yervoy (ipilimumab) and PD-1 blocker Opdivo (nivolumab), However, it has since lost ground to rival Merck
-
Keytruda hits survival targets in first-line kidney cancer
Bristol-Myers Squibb’s cancer immunotherapy pairing of PD-1 inhibitor Opdivo (nivolumab) and CTLA4 inhibitor Yervoy (ipilimumab) was approved earlier this year as first-line treatment for RCC, but only
-
Merck’s Bavencio joins first-line kidney cancer face-off
Both combinations could challenge the position of Bristol-Myers Squibb’s Opdivo (nivolumab) and Yervoy (ipilimumab), which has started to replace Sutent and other TKIs like Exelixis’ Cabometyx (cabozantinib) as the
More from news
Approximately 8 fully matching, plus 145 partially matching documents found.
Latest Intelligence
-
Combined immunotherapies – potential and pitfalls
This contrasts with the approved ipilimumab-nivolumab combination therapy, which costs $256, 000 a year, according to the researchers.
-
Cancer immunotherapy: What's on the horizon?
drug Yervoy (ipilimumab) in an early-stage trial.
-
Pharma deals in February 2015
As well as the already marketed Yervoy (ipilimumab) and recently FDA approved Opdivo (nivolumab), BMS has four additional immuno-oncology drugs in clinical trial.
-
Pharma deals during July 2014
Opdivo (nivolumab), an anti-PD-1 antibody that is approved in Japan for unresectable melanoma, and Yervoy (ipilimumab), an anti-CTLA-4 antibody that is FDA approved for late-stage melanoma.
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest appointments
-
BMS appoints oncology development head
On moving to the US in 2006, Dr Namouni took over responsibility for metastatic colorectal cancer treatment Erbitux (cetuximab), before serving as development lead for Opdivo (nivolumab) and Yervoy (ipilimumab).
-
CytomX appoints Rachel Humphrey chief medical officer
drug Yervoy (ipilimumab).
-
Jonathan Dickinson joins Ariad from BMS
population. He has previous experience in the commercialisation of cancer drugs, serving for the past three years as BMS' European brand lead for Yervoy (ipilimumab).
More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest from PMHub
-
Immunotherapies in oncology: the future of cancer treatment lies in combinations and partnerships
Yervoy (ipilimumab, Bristol-Myers Squibb) is a first-generation agent which was approved by the FDA in 2011 for advanced melanoma.
-
Immunotherapy in oncology
This was the case with the development of ipilimumab (Yervoy) where response-based endpoints (overall response rate [ORR] and progression free survival [PFS]) were the primary endpoints of the phase II ... This led to a changing of the primary
-
ASCO 2015: What you missed in Chicago
In terms of winners here, BMS is likely to redefine the standard of care in Melanoma with the Opdivo/Yervoy (ipilimumab) combination. ... Patel SP et al Mol Cancer Ther 2015[2] Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.
Featured jobs
-
Account Director, Medical Education
-
Salary TBC
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
-
Associate Director
-
£75, 000-90, 000
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
-
Medical Writer
-
Salary TBC
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
-
Senior Medical Writer
-
Salary TBC
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
-
Account Manager / Account Director
-
Competative
- Senior Account Director development role to Business Director, H...
-
Excellent package
- Account Manager / Senior Account Manager
-
35, 000-40, 000
- Global Business Development Director – Health Education
-
excellent commission
Subscribe to our email news alerts
- Europe closer to biosimilar rule change, despite fierce resistance from pharma
- Immunomedics craters after FDA rejects breast cancer ADC
- NHS England sees off AbbVie's Hep C legal challenge
- FDA expecting boom in cell and gene therapies
- Moving annual total (MAT)
- Novartis forges AI alliance with Oxford University
- J&J earnings top expectations, but feels the squeeze in US
- Researchers reverse Alzheimer’s memory loss in mice
- Editas CEO exits the CRISPR firm ahead of first clinical trial
- A dynamic and challenging environment – what it’s like starting a career in MedComms
- UniQure cleared to start Huntington gene therapy trial
- HSJ Partnership Awards 2019 shortlist announced
PMHub
Cuttsy + Cuttsy
How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...
Latest intelligence
- Unlocking the potential of science and technology in the UK
- Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
- NHS regional footprints
- What to expect from 2019...
- Not another weight-loss ad
- Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
Quick links
Infographics
